• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma.

作者信息

Jin Haoli, Reed James C, Liu Sean T H, Ho Hsi-En, Lopes Joao Pedro, Ramsey Nicole B, Waqar Omar, Rahman Farah, Aberg Judith A, Bouvier Nicole M, Cunningham-Rundles Charlotte

机构信息

Icahn School of Medicine at Mount Sinai, Division of Allergy and Clinical Immunology, Departments of Medicine and Pediatrics, New York, NY.

Mount Sinai Kravis Children's Hospital, Pediatric Physician Scientist Residency Program, New York, NY.

出版信息

J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3594-3596.e3. doi: 10.1016/j.jaip.2020.08.059. Epub 2020 Sep 15.

DOI:10.1016/j.jaip.2020.08.059
PMID:32947026
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7490621/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52f/7490621/25662f1db8b2/fx1a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52f/7490621/9dd367866a2c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52f/7490621/25662f1db8b2/fx1a_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52f/7490621/9dd367866a2c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e52f/7490621/25662f1db8b2/fx1a_lrg.jpg

相似文献

1
Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma.三名因新冠病毒疾病住院治疗的X连锁无丙种球蛋白血症患者接受恢复期血浆治疗后病情好转。
J Allergy Clin Immunol Pract. 2020 Nov-Dec;8(10):3594-3596.e3. doi: 10.1016/j.jaip.2020.08.059. Epub 2020 Sep 15.
2
Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19.在一名伴有低丙种球蛋白血症和 COVID-19 的 MM 患者中，使用恢复期血浆成功地转移了抗 SARS-CoV-2 免疫。
Blood Adv. 2020 Oct 13;4(19):4864-4868. doi: 10.1182/bloodadvances.2020002595.
3
Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.一名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的X连锁无丙种球蛋白血症患者在输注新冠康复者血浆后迅速康复。
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2793-2795. doi: 10.1016/j.jaip.2020.06.046. Epub 2020 Jul 8.
4
Clinical findings in a patient with haemophilia A affected by COVID-19.一名甲型血友病患者感染新型冠状病毒肺炎的临床发现。
Haemophilia. 2020 Jul;26(4):e214-e216. doi: 10.1111/hae.14000. Epub 2020 Apr 13.
5
COVID-19: Main therapeutic options.新型冠状病毒肺炎：主要治疗选择
Tunis Med. 2020 Apr;98(4):299-303.
6
Antibody-based therapies for COVID-19: Can Europe move faster?针对 COVID-19 的抗体疗法：欧洲能否行动更快？
PLoS Med. 2020 May 5;17(5):e1003127. doi: 10.1371/journal.pmed.1003127. eCollection 2020 May.
7
A serological assay to detect SARS-CoV-2 seroconversion in humans.用于检测人类 SARS-CoV-2 血清转化的血清学检测方法。
Nat Med. 2020 Jul;26(7):1033-1036. doi: 10.1038/s41591-020-0913-5. Epub 2020 May 12.
8
Convalescent plasma for COVID-19: Promising, not proven.恢复期血浆治疗 COVID-19：前景可期，证据不足。
Cleve Clin J Med. 2020 Nov 2;87(11):664-670. doi: 10.3949/ccjm.87a.ccc056.
9
Our recommendations for acute management of COVID-19.我们对新型冠状病毒肺炎急性处理的建议。
Crit Care. 2020 May 8;24(1):207. doi: 10.1186/s13054-020-02930-6.
10
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.两名 X 连锁无丙种球蛋白血症患者因 COVID-19 出现肺炎表现，但已康复。
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569. doi: 10.1111/pai.13263. Epub 2020 May 19.

引用本文的文献

1
COVID-19 vaccine updates for people under different conditions.不同人群的 COVID-19 疫苗更新信息。
Sci China Life Sci. 2024 Nov;67(11):2323-2343. doi: 10.1007/s11427-024-2643-1. Epub 2024 Jul 29.
2
Pharmacokinetics of convalescent plasma therapy in a COVID-19 patient with X-linked Agammaglobulinemia.一名患有X连锁无丙种球蛋白血症的COVID-19患者恢复期血浆治疗的药代动力学
Clin Immunol Commun. 2022 Dec;2:57-61. doi: 10.1016/j.clicom.2022.03.001. Epub 2022 Mar 10.
3
Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review.

本文引用的文献

1
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.恢复期血浆治疗重症 COVID-19：一项倾向评分匹配对照研究。
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
2
An inflammatory cytokine signature predicts COVID-19 severity and survival.炎症细胞因子特征可预测 COVID-19 严重程度和存活情况。
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.
3
Early safety indicators of COVID-19 convalescent plasma in 5000 patients.5000 例 COVID-19 恢复期血浆治疗的早期安全性指标。
患有先天性免疫缺陷（原发性免疫缺陷）儿童的新型冠状病毒2型感染严重程度：一项系统评价
Allergy Asthma Clin Immunol. 2023 Aug 9;19(1):69. doi: 10.1186/s13223-023-00831-1.
4
COVID-19 after rituximab therapy in cSLE patients.利妥昔单抗治疗后cSLE患者的COVID-19
Ther Adv Vaccines Immunother. 2023 Jun 21;11:25151355231181242. doi: 10.1177/25151355231181242. eCollection 2023.
5
COVID-19 Pneumonia with Migratory Pattern in Agammaglobulinemic Patients: A Report of Two Cases and Review of Literature.免疫球蛋白缺乏症患者的 COVID-19 肺炎伴游走性表现：两例病例报告及文献复习。
Tomography. 2023 Apr 23;9(3):894-900. doi: 10.3390/tomography9030073.
6
COVID-19 relapse associated with SARS-CoV-2 evasion from CD4 T-cell recognition in an agammaglobulinemia patient.一名无丙种球蛋白血症患者中，新冠病毒感染复发与严重急性呼吸综合征冠状病毒2逃避CD4 T细胞识别有关。
iScience. 2023 May 19;26(5):106685. doi: 10.1016/j.isci.2023.106685. Epub 2023 Apr 20.
7
B lymphocytes in COVID-19: a tale of harmony and discordance.COVID-19 中的 B 淋巴细胞：一个和谐与失调的故事。
Arch Virol. 2023 Apr 29;168(5):148. doi: 10.1007/s00705-023-05773-y.
8
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.COVID-19 恢复期血浆治疗免疫功能低下患者：系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
9
High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform.高通量、靶向 MHC Ⅰ类免疫肽组学的功能遗传学筛选平台。
Nat Biotechnol. 2023 Jul;41(7):980-992. doi: 10.1038/s41587-022-01566-x. Epub 2023 Jan 2.
10
Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity.严重急性呼吸综合征冠状病毒 2 感染和 COVID-19 对先天性免疫缺陷病患者的影响。
J Allergy Clin Immunol. 2023 Apr;151(4):818-831. doi: 10.1016/j.jaci.2022.11.010. Epub 2022 Dec 13.
J Clin Invest. 2020 Sep 1;130(9):4791-4797. doi: 10.1172/JCI140200.
4
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia.B细胞在新冠病毒疾病中可能发挥的作用？来自无丙种球蛋白血症患者的启示。
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4. doi: 10.1016/j.jaci.2020.04.013. Epub 2020 Apr 22.
5
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.两名 X 连锁无丙种球蛋白血症患者因 COVID-19 出现肺炎表现，但已康复。
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569. doi: 10.1111/pai.13263. Epub 2020 May 19.
6
Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.中国武汉 COVID-19 患者恢复期血浆治疗。
J Med Virol. 2020 Oct;92(10):1890-1901. doi: 10.1002/jmv.25882. Epub 2020 Jun 29.
7
Deployment of convalescent plasma for the prevention and treatment of COVID-19.恢复期血浆在 COVID-19 预防和治疗中的应用。
J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.
8
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
9
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.